Last reviewed · How we verify
Reference drug
At a glance
| Generic name | Reference drug |
|---|---|
| Also known as | Fluconazole capsule 50mg, Crestor 20 mg Tablet, NSAIDs, D744, D935 |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (PHASE1)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- Food as Medicine Study (NA)
- The Impact of Music Medicine on Preterm Brain Development and Behavior (NA)
- A Bioequivalence Study of PP3M in Patients With Schizophrenia (NA)
- Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
- Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reference drug CI brief — competitive landscape report
- Reference drug updates RSS · CI watch RSS
- Pfizer portfolio CI